ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene.

ORKAMBI should not be used in patients other than those who have two copies of the F508del mutation in their CFTR gene.

It is not known if ORKAMBI is safe and effective in children under 12 years of age.

Please visit http://www.orkambi.com/ to learn more about its approval, who should take it, and how to start your conversation with your healthcare provider. 

« Previous Page